External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>Axis New Year Picks: We are proud to announce our exclusive report: Axis New Year Picks 2023 – Focus on 6 Golden Themes.</li><li>The report contains deeply-researched 9 stocks that are best-placed to deliver excellent performance in 2023 and thereby strengthen your investment portfolio.</li><li>Axis Alpha: Axis Alpha reported an excellent monthly strike rate of 78% in Dec’22. It continued to deliver robust returns with absolute profits of over 5.4 Lc since its inception in May’20.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Axis New Year Picks: We are proud to announce our exclusive report: Axis New Year Picks 2023 – Focus on 6 Golden Themes.The report contains deeply-researched 9 stocks that are best-placed to deliver excellent performance in 2023 and thereby strengthen your investment portfolio.Axis Alpha: Axis Alpha reported an excellent monthly strike rate of 78% in Dec’22. It continued to deliver robust returns with absolute profits of over 5.4 Lc since its inception in May’20.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

External broker reports(aggregated public sources), Nirmal Bang

Nirmal Bang

A Relationship Beyond Broking

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

Equity Bottom-Up

IOL Chemicals And Pharmaceuticals Ltd / Equity Bottom-Up

<div><div><div><div><ul><li>JB Chem reported revenue at Rs6,246mn, up 18.2% YoY and 4% QoQ. EBITDA stood at Rs1,249mn, up .8% YoY but down 2.5% QoQ.</li><li>EBITDA margin stood at 20%, down 344bps YoY and 133bps QoQ. PAT stood at Rs849mn, down 15.7% YoY but up 1.2% QoQ.</li><li>Domestic Formulations sales at Rs2,870mn grew by 29.9% YoY and 3.2% QoQ. </li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

JB Chem reported revenue at Rs6,246mn, up 18.2% YoY and 4% QoQ. EBITDA stood at Rs1,249mn, up .8% YoY but down 2.5% QoQ.EBITDA margin stood at 20%, down 344bps YoY and 133bps QoQ. PAT stood at Rs849mn, down 15.7% YoY but up 1.2% QoQ.Domestic Formulations sales at Rs2,870mn grew by 29.9% YoY and 3.2% QoQ. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

J B Chemicals and Pharmaceuticals - Strong Growth in Contract Manufacturing Bus

India

IOL Chemicals and Pharmaceuticals Limited manufactures active pharmaceutical ingredients (APIs) such as ibuprofen and organic chemicals. The Company produces, ethyl acetate, isobutyl benzene (IBB), monochloroacetic acid (MCA), acetyl chloride, and bulk ibuprofen.

IOL Chemicals And Pharmaceuticals Ltd (ICP IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IOL Chemicals And Pharmaceuticals Ltd (ICP IN)

Axis Research Scorecard Report - Dec 22

Axis New Year Picks: We are proud to announce our exclusive report: Axis New Year Picks 2023 – Focus on 6 Golden Themes.

Axis Direct

J B Chemicals and Pharmaceuticals - Strong Growth in Contract Manufacturing Bus

JB Chemicals’ (JB Chem) 4QFY22 net profit (Rs849mn) was better than our expectation. revenue at Rs6,246mn was 4.5% above our estimate.

Nirmal Bang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)